BioAge Labs, Inc. (BIOA)
| Market Cap | 785.04M +428.9% |
| Revenue (ttm) | 10.32M +611.0% |
| Net Income | -89.93M |
| EPS | -2.39 |
| Shares Out | 44.45M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 481,511 |
| Open | 18.17 |
| Previous Close | 18.72 |
| Day's Range | 17.37 - 18.28 |
| 52-Week Range | 3.67 - 24.00 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 49.86 (+182.33%) |
| Earnings Date | May 8, 2026 |
About BIOA
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular e... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for BIOA stock is "Strong Buy." The 12-month stock price target is $49.86, which is an increase of 182.33% from the latest price.
News
BioAge Labs initiated with a Buy at BTIG
BTIG initiated coverage of BioAge Labs (BIOA) with a Buy rating and $40 price target BioAge is a clinical-stage biopharmaceutical company focused on treating disease related to human aging, the…
BioAge Labs Transcript: R&D Day 2026
BGE-102, an oral NLRP3 inhibitor, showed robust Phase I efficacy and safety, with up to 86% CRP reduction and strong CNS/retinal penetration. Phase II trials in cardiovascular risk and diabetic macular edema are underway, supported by a strong cash position and expert validation of the anti-inflammatory strategy.
BioAge Labs reports Q1 EPS (52c), consensus (63c)
Reports Q1 revenue $2.77M, consensus $1.08M. “The positive topline Phase 1 data we reported for BGE-102 in April reinforce our conviction that we have a potential best-in-class NLRP3 inhibitor: a…
BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates
Positive topline Phase 1 data for BGE-102, demonstrating potential best-in-class reductions among oral NLRP3 inhibitors in inflammatory biomarkers of cardiovascular risk Phase 2 dose-ranging proof-of-...
BioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026
Live webcast on Friday, May 8, 2026, beginning at 12:30 PM ET Event will feature Phase 1 clinical data for BGE-102 and the therapeutic rationale for development in atherosclerotic cardiovascular disea...
BioAge Labs reports results for Phase 1 trial of BGE-102, to initiate Phase 2
BioAge Labs (BIOA) reported results from the Phase 1 clinical trial of BGE-102, a novel, orally available, brain-penetrant small molecule NLRP3 inhibitor. The full dataset, which includes a newly anno...
BioAge Labs Transcript: Study result
Phase I results for BGE-102 showed up to 86% CRP reduction and strong safety in obese subjects, with most patients reaching CRP below 2 mg/L. The drug demonstrated potent inhibition of IL-1β and IL-6, strong CNS/ocular penetration, and supports advancement into phase II cardiovascular and ophthalmology trials.
BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP
120 mg and newly announced 60 mg once-daily doses each achieved ≥85% median hsCRP reductions in participants with obesity and elevated baseline inflammation BGE-102 was well tolerated across all dose ...
BioAge Labs Transcript: 25th Annual Needham Virtual Healthcare Conference
The company is advancing BGE-102, a novel NLRP3 inhibitor, into phase I and II trials for cardiovascular and ophthalmology indications, with promising early efficacy and safety data. Strong financials and sector interest support a robust pipeline, including APJ agonists for obesity.
BioAge Labs to Present at 25th Annual Needham Virtual Healthcare Conference
EMERYVILLE, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for ...
BioAge Labs initiated with a Buy at Needham
Needham initiated coverage of BioAge Labs (BIOA) with a Buy rating and $50 price target The firm is “bullish” on the company’s lead asset BGE-102, an oral, NLRP3 inhibitor in…
BioAge Labs files automatic mixed securities shelf
16:23 EDT BioAge Labs (BIOA) files automatic mixed securities shelf
BioAge Labs price target raised to $52 from $15 at Citi
Citi raised the firm’s price target on BioAge Labs (BIOA) to $52 from $15 and keeps a Buy rating on the shares. The firm sees a “compelling” outlook for the…
BioAge Labs Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
The company presented strong phase I data for its oral NLRP3 inhibitor, showing best-in-class CRP reduction and favorable safety in obese patients. Key upcoming milestones include full phase I data, a three-month monotherapy trial, and a DME proof-of-concept study, with additional programs in obesity and ongoing pharma collaborations.
BioAge Labs initiated with an Outperform at Oppenheimer
Oppenheimer initiated coverage of BioAge Labs (BIOA) with an Outperform rating and $60 price target. The firm is optimistic on the company’s lead asset BGE-102’s NLRP3 inhibition. The “highly validate...
BioAge Labs upgraded to Buy from Hold at Jefferies
Jefferies analyst Roger Song upgraded BioAge Labs (BIOA) to Buy from Hold with a price target of $62, up from $9. The firm, which updated its thesis on BGE-102 and…
BioAge Labs price target raised to $23 from $12 at Morgan Stanley
Morgan Stanley raised the firm’s price target on BioAge Labs (BIOA) to $23 from $12 and keeps an Equal Weight rating on the shares. Early Phase 1 BGE-102 data indicate…
BioAge Labs initiated with an Overweight at Piper Sandler
Piper Sandler initiated coverage of BioAge Labs (BIOA) with an Overweight rating and $73 price target The company’s BGE-102 is an oral QD CNS-penetrant NLRP3 inhibitor small-molecule with “strong” Pha...
BioAge Announces Pricing of Upsized $115.0 Million Public Offering
EMERYVILLE, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) ("BioAge", “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates f...
BioAge Labs announces $75M common stock offering
BioAge Labs (BIOA) announced a proposed underwritten public offering in which it intends to offer and sell, subject to market and other conditions, up to $75M of shares of its…
BioAge Announces Proposed Public Offering
EMERYVILLE, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates f...
BioAge Labs management to meet with Piper Sandler
Meeting to be held in Boston on January 28 hosted by Piper Sandler.
BioAge Labs announces expansion of its BGE-102 development program
BioAge Labs (BIOA) announced expansion of its BGE-102 development program into ophthalmology, with an initial proof-of-concept, POC, study in patients with diabetic macular edema, DME. BGE-102 is a po...
BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026
BGE-102 has the potential for therapeutic retinal exposure with oral delivery, reducing treatment burden in ocular indications currently treated with intravitreal therapies
BioAge Labs announces additional interim data from Phase 1 trial of BGE-102
BioAge Labs (BIOA) announced additional positive interim data from the ongoing Phase 1 clinical trial evaluating BGE-102, a potent, structurally novel, orally available, brain-penetrant small molecule...